BioXcel Therapeutics (BTAI) Net Margin (2022 - 2026)
BioXcel Therapeutics (BTAI) recorded quarterly Net Margin of 6654.37% in Q1 2026, down 18.65% quarter-over-quarter from 5608.2% in Q4 2025, and up 156765.0% on a YoY basis from N/an in Q1 2025.
BioXcel Therapeutics (BTAI) Net Margin (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' Net Margin history runs 5 years deep, the most recent figure standing at 6654.37% for Q1 2026.
- In Q1 2026, Net Margin rose 156765.0% year-over-year to 6654.37%; the TTM figure through Mar 2026 stood at 9688.38% (down 610069.0% YoY), while the FY2025 annual figure was 10339.41%, down 683963.0% from the prior year.
- Net Margin was 6654.37% for Q1 2026 at BioXcel Therapeutics, down from 5608.2% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 1832.34% in Q2 2024 to a low of 30401.46% in Q3 2022.
- Historically, Net Margin has averaged 12361.54% across 5 years, with a median of 8629.44% in 2024.
- The sharpest annual moves came in 2024 and 2025: Net Margin soared 2073930 bps in 2024, then plunged 1437683 bps in 2025.
- A 5-year view of Net Margin shows it stood at 23052.94% in 2022, then surged by 75 bps to 5866.22% in 2023, then jumped by 35 bps to 3807.38% in 2024, then tumbled by 47 bps to 5608.2% in 2025, then slipped by 19 bps to 6654.37% in 2026.
- The last three Net Margin figures came in at 6654.37% (Q1 2026), 5608.2% (Q4 2025), and 18739.8% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 9.19% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 26.57% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 35.18% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 2.94% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 24.30% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 4.16% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -168.42% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -15.15% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 31.38% |
| 10 | BioXcel Therapeutics | 25.46 Mn | 25.46 Mn | -77,000.00 | -6,654.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,654.37% |
| Dec 31, 2025 | -5,608.20% |
| Sep 30, 2025 | -18,739.80% |
| Jun 30, 2025 | -16,209.17% |
| Mar 31, 2025 | -8,222.02% |
| Dec 31, 2024 | -3,807.38% |
| Sep 30, 2024 | -8,629.44% |
| Jun 30, 2024 | -1,832.34% |
| Mar 31, 2024 | -4,608.76% |
| Dec 31, 2023 | -5,866.22% |
| Sep 30, 2023 | -14,693.26% |
| Jun 30, 2023 | -11,749.67% |
| Mar 31, 2023 | -25,348.06% |
| Dec 31, 2022 | -23,052.94% |
| Sep 30, 2022 | -30,401.46% |